GlassScriptPhysician profile
Jessica Mann
NPI 1336793751
$2,737.81
in general payments reported to CMS, 2019-2025
34 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.12 · 2022: $54.41 · 2023: $30.62 · 2024: $1,018 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,652.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $347.83 | 2024-2025 | |
| Ardelyx, INC. | $300.15 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $243.52 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $198.43 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.96 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Astrazeneca Pharmaceuticals LP | $187.44 | 2024-2025 | Farxiga, Airsupra |
| Abbvie INC. | $172.41 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.51 | 2024-2025 | Trintellix |
| Lilly USA, LLC | $115.95 | 2024 | Jardiance, Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.90 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $80.14 | 2025 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $72.43 | 2025 | Spravato |
| Lundbeck LLC | $62.67 | 2024 | Rexulti |
| Mylan Specialty L.P. | $54.02 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.00 | 2024 | Jardiance, Ofev |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $50.00 | 2024-2025 | |
| Baxter Healthcare | $37.11 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $25.97 | 2025 | Arikayce |
| Antares Pharma, INC. | $24.04 | 2025 | Xyosted |
| Philips North America LLC | $22.84 | 2025 | Vest Therapy Und |
| Smith+Nephew, INC. | $21.12 | 2024 | Regranex, Collagenase Santyl |
| Boston Scientific Corporation | $19.72 | 2025 | Watchman Access System |
| Nalu Medical, INC. | $18.86 | 2022 | |
| Corcept Therapeutics | $18.81 | 2025 | Korlym |
| Collegium Pharmaceutical, INC. | $18.02 | 2022 | |
| Scilex Pharmaceuticals INC. | $17.96 | 2025 | |
| Viatris Specialty LLC | $17.59 | 2025 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $17.53 | 2022 | |
| Averitas Pharma INC. | $17.23 | 2023 | Qutenza |
| Esperion Therapeutics, INC. | $16.50 | 2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $16.04 | 2025 | Rexulti |
| Verona Pharma, INC. | $13.97 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $13.58 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $13.56 | 2024 | Capvaxive, Gardasil 9, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.